The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Chiral resolution, or enantiomeric resolution, is a process in stereochemistry for the separation of racemic mixture into their enantiomers. It is an important tool in the production of optically active compounds, including drugs. Another term with the same meaning is optical resolution. The use of chiral resolution to obtain enantiomerically pure compounds has the disadvantage of necessarily discarding at least half of the starting racemic mixture. Asymmetric synthesis of one of the enantiomers is one means of avoiding this waste.
Luteinizing hormone (LH, also known as luteinising hormone, lutropin and sometimes lutrophin) is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, an acute rise of LH known as an LH surge, triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with follicle-stimulating hormone (FSH).
PLGA is typically synthesized by ring-opening polymerization of the cyclic dimers lactide and glycolide, a method widely used because it allows better control over molecular weight and copolymer composition than direct condensation methods. Other reports show direct polycondensation of lactic acid and glycolic acid as another method, but this approach gives lower molecular weight material and is less suitable for producing controlled, high-performance PLGA grades. Common catalysts include tin(II) 2-ethylhexanoate and related organometallic catalysts, which are widely used in melt polymerization because of their activity and practical availability.
These physiological changes in the decomposers also alter the local environment in a way that allows certain minerals to be deposited, while others remain in solution. Generally, however, a fossilizing egg's shell keeps the same calcite it had in life, which allows scientists to study its original structure millions of years after the developing dinosaur hatched or died. However, eggs can also sometimes be altered after burial. This process is called diagenesis. One form of diagenesis is a microscopic cross-hatched pattern imposed on the eggshell by the pressure of being buried deeply. If the pressure gets severe enough, sometimes the eggshell's internal microscopic structure can be completely destroyed. Diagenesis can also happen chemically in addition to physically. The chemical conditions of a decomposing egg can make it easy for silica to be incorporated into eggshell and damage its structure. When iron-bearing substances alter eggshell it can be obvious because compounds like hematite, pyrite, and iron sulfide can turn the shell blackish or rusty colors.
Sources: en.wikipedia.org
== Overdose == Enobosarm has been assessed in clinical trials at doses ranging from 0.1 to 18 mg/day. However, most research has been done at doses of 0.1 to 3 mg/day, with two phase 3 clinical trials using a dosage of 3 mg/day. A few small phase 1 and phase 2 trials of enobosarm for breast cancer have employed doses of 9 to 18 mg/day. Larger, phase 3 trials of enobosarm at a dose of 9 mg/day for breast cancer (e.g., ARTEST, n=210) are now underway. Doses of up to 100 mg have been assessed in single-dose pharmacokinetic studies and doses of up to 30 mg/day have been given in short 14-day pharmacokinetic studies. Enobosarm sold via black-market Internet suppliers and used non-medically is often taken at much higher doses than those used widely in clinical trials (e.g., 10–30 mg/day), with unknown adverse effects and risks.
Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the structure of the neuropeptide somatostatin, which is an endogenous hormone found in the human body. The somatostatin receptors are G protein-coupled receptors. Somatostatin receptor subtypes in humans include sstr1, 2A, 2 B, 3, 4, and 5. While normally expressed in the gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS), they are expressed in different types of tumours. The predominant subtype in cancer cells is the ssrt2 subtype, which is expressed in neuroblastomas, meningiomas, medulloblastomas, breast carcinomas, lymphomas, renal cell carcinomas, paragangliomas, small cell lung carcinomas, and hepatocellular carcinomas. As a radiopharmaceutical compound that is selective for somatostatin receptors, there is research being done for these radiolabeled compounds to act as diagnostic tests in PET scans for neuroendocrine tumors and other tumors not previously targeted with radiolabeled somatostatin receptor agonists, and to act as radiopharmaceutical therapeutic compound, more specifically to conduct peptide radionuclide receptor therapy. Some non-radiopharmaceutical compounds that are developed as competitive inhibitors of somatostatin, such as the hormone antagonist cyclosomatostatin.
According to historian Asif Siddiqi, Korolev's accomplishments marked "the absolute zenith of the Soviet space program, one never, ever attained since." There was a two-year pause in Soviet piloted space flights while Voskhod's replacement, the Soyuz spacecraft, was designed and developed.
=== Services === As of 2025–26, the services sector was the largest contributor to Pakistan's GDP, accounting for 58.42% of GDP. The sector accounted for 41.6% of total employment in 2024–25. In the International Telecommunication Union's ICT Development Index, Pakistan's score increased from 56.4 in 2025 to 67.7 in 2026, an increase of 20% from 2025. Approximately 57% of Pakistan's population used the Internet in 2024. In fiscal year 2023–24, Pakistan's ICT exports rose to a record $2.6 billion. Pakistan ranks among the world's top five freelancing markets, with an estimated three million freelancers. During the first ten months of fiscal year 2025–26, freelancers earned more than US$950 million in foreign exchange.
Drug discovery is the initial phase of research focused on identifying and validating new chemical compounds (lead compounds) that are intended to treat a disease. Drug design is an inventive method used within the discovery phase and encompasses the designing of molecules that are complementary in polarity (charge) and shape (stereochemistry) to a given biomolecular target. After a lead compound has been identified through drug discovery, drug development involves bringing the drug to the market. Drug discovery is related to pharmacoeconomics, which is the sub-discipline of health economics that considers the value of drugs. Pharmacoeconomics evaluates the cost and benefits of drugs in order to guide optimal healthcare resource allocation. The techniques used for the formulation and manufacturing of drugs are studied by pharmaceutical engineering, a branch of engineering. Safety pharmacology specializes in detecting and investigating potential undesirable and adverse effects of drugs.
Sources: en.wikipedia.org
=== Variation === The formyl group is not strictly required for initiation. Bacteria with their formyltransferase knocked out, which prevents Met-tRNAfMet (i.e. methionine loaded onto tRNAfMet) from turning into fMet-tRNAfMet, can have varying degrees of residual ability to start protein synthesis. E. coli, S. pneumoniae and B. subtilis show almost no remaining translation ability, while P. aeruginosa, S. aureus, H. influenzae, and possibly S. faecalis still churn out plenty of protein. In P. aeruginosa, this ability is facilitated by bacterial initiation factor 2, which can carry both Met-tRNAfMet and fMet-tRNAfMet to the ribosome.
In general, drugs like suvomipic are only thought to have potential effectiveness for a given follicle if it is still intact, undamaged, and merely dormant. Hair follicles are known to undergo progressive damage from low-grade microinflammation and reduced blood flow in androgenic alopecia, resulting not only in dormancy but also in perifollicular fibrosis and associated follicular miniaturization. In addition, in more advanced or later-stage cases, there can be arrector pili muscle detachment and micro-scarring. These sequelae are thought to limit the potential for follicular regeneration.
Among the specimens studied was a previously undescribed specimen of Sinosauropteryx, IVPP V14202, though this specimen is now the holotype of a separate genus Huadanosaurus. By examining melanosome structure and distribution, Zhang and colleagues were able to confirm the presence of light and dark bands of colour in the tail feathers of this specimen (now the holotype of Huadanosaurus) like that of a red panda. Furthermore, the team was able to compare melanosome types to those of modern birds to determine a general range of colour. From the presence of phaeomelanosomes, spherical melanosomes that make and store red pigment, they concluded that the darker feathers of this specimen were chestnut or reddish brown in colour. More research on the coloration of Sinosauropteryx based on three specimens (NIGP 127586, NIGP 127587, and IVPP V12415) reveals that it had a raccoon-like bandit mask and countershading patterns most likely associated with an open habitat, indicating that the Jehol likely had a range of habitat types.
== Diagnosis == In 1980, the American College of Rheumatology agreed on diagnostic criteria for scleroderma. Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anticentromere and anti-Scl-70 antibodies), and occasionally by biopsy. Of the antibodies, 90% have a detectable antinuclear antibody. Anticentromere antibody is more common in the limited form (80–90%) than in the diffuse form (10%), and anti-Scl-70 is more common in the diffuse form (30–40%) and in African-American patients (who are more susceptible to the systemic form). Other conditions may mimic systemic sclerosis by causing hardening of the skin. Diagnostic hints that another disorder is responsible include the absence of Raynaud's phenomenon, a lack of abnormalities in the skin on the hands, a lack of internal organ involvement, and a normal antinuclear antibodies test result.
Krypton is considered to be a non-toxic asphyxiant. Being lipophilic, krypton has a significant anaesthetic effect (although the mechanism of this phenomenon is still not fully clear, there is good evidence that the two properties are mechanistically related), with narcotic potency seven times greater than air, and breathing an atmosphere of 50% krypton and 50% natural air (as might happen in the locality of a leak) causes narcosis in humans similar to breathing air at four times atmospheric pressure. This is comparable to scuba diving at a depth of 30 m (100 ft) and could affect anyone breathing it.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.